Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea
· Delayed Price · Currency is KRW 10,220
+30 (0.29%)
Mar 10, 2026, 2:40 PM KST
Daewon Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 218,407 | 305,427 | 331,930 | 393,197 | 342,999 | 380,715 | Upgrade
|
| Market Cap Growth | -28.69% | -7.99% | -15.58% | 14.64% | -9.91% | 13.65% | Upgrade
|
| Enterprise Value | 371,287 | 434,054 | 418,509 | 453,068 | 412,231 | 412,859 | Upgrade
|
| Last Close Price | 10190.00 | 13957.75 | 15014.55 | 17630.58 | 14913.94 | 16349.11 | Upgrade
|
| PE Ratio | - | 21.49 | 13.88 | 12.31 | 49.08 | 21.58 | Upgrade
|
| Forward PE | 28.70 | 9.77 | 9.77 | 9.77 | 9.77 | 9.77 | Upgrade
|
| PS Ratio | 0.37 | 0.51 | 0.63 | 0.82 | 0.97 | 1.23 | Upgrade
|
| PB Ratio | 0.83 | 1.07 | 1.26 | 1.58 | 1.57 | 1.79 | Upgrade
|
| P/TBV Ratio | 1.10 | 1.27 | 1.37 | 1.74 | 1.77 | 1.88 | Upgrade
|
| P/FCF Ratio | 12.59 | - | 8.41 | 21.36 | 18.73 | 27.98 | Upgrade
|
| P/OCF Ratio | 5.10 | 10.17 | 6.42 | 14.89 | 15.30 | 15.26 | Upgrade
|
| PEG Ratio | 0.73 | 0.49 | 0.49 | 0.49 | 0.49 | 0.49 | Upgrade
|
| EV/Sales Ratio | 0.63 | 0.73 | 0.79 | 0.95 | 1.16 | 1.34 | Upgrade
|
| EV/EBITDA Ratio | 15.93 | 9.28 | 8.40 | 7.28 | 11.11 | 10.41 | Upgrade
|
| EV/EBIT Ratio | - | 16.27 | 12.98 | 10.56 | 21.36 | 17.22 | Upgrade
|
| EV/FCF Ratio | 21.40 | - | 10.61 | 24.62 | 22.52 | 30.35 | Upgrade
|
| Debt / Equity Ratio | 0.81 | 0.66 | 0.55 | 0.47 | 0.57 | 0.25 | Upgrade
|
| Debt / EBITDA Ratio | 9.67 | 4.00 | 2.93 | 1.87 | 3.34 | 1.32 | Upgrade
|
| Debt / FCF Ratio | 12.30 | - | 3.70 | 6.33 | 6.77 | 3.86 | Upgrade
|
| Net Debt / Equity Ratio | 0.55 | 0.50 | 0.44 | 0.28 | 0.32 | 0.20 | Upgrade
|
| Net Debt / EBITDA Ratio | 6.58 | 3.02 | 2.33 | 1.12 | 1.86 | 1.06 | Upgrade
|
| Net Debt / FCF Ratio | 8.37 | -29.22 | 2.94 | 3.78 | 3.78 | 3.08 | Upgrade
|
| Asset Turnover | 0.98 | 1.10 | 1.10 | 1.09 | 0.93 | 0.93 | Upgrade
|
| Inventory Turnover | 2.97 | 2.86 | 2.76 | 3.01 | 2.69 | 2.49 | Upgrade
|
| Quick Ratio | 0.64 | 0.62 | 0.56 | 0.89 | 1.07 | 0.93 | Upgrade
|
| Current Ratio | 1.12 | 1.19 | 1.15 | 1.62 | 1.77 | 2.09 | Upgrade
|
| Return on Equity (ROE) | -6.75% | 3.68% | 9.15% | 13.13% | 3.07% | 8.25% | Upgrade
|
| Return on Assets (ROA) | -0.04% | 3.06% | 4.19% | 6.07% | 3.16% | 4.52% | Upgrade
|
| Return on Invested Capital (ROIC) | -0.08% | 4.14% | 8.38% | 11.21% | 2.75% | 7.10% | Upgrade
|
| Return on Capital Employed (ROCE) | -0.10% | 7.00% | 9.90% | 13.20% | 5.90% | 8.60% | Upgrade
|
| Earnings Yield | -7.34% | 4.65% | 7.21% | 8.12% | 2.04% | 4.63% | Upgrade
|
| FCF Yield | 7.94% | -1.58% | 11.88% | 4.68% | 5.34% | 3.57% | Upgrade
|
| Dividend Yield | 2.80% | 2.15% | - | - | 1.30% | 0.95% | Upgrade
|
| Payout Ratio | - | 44.75% | 30.69% | 12.90% | 44.93% | 28.54% | Upgrade
|
| Buyback Yield / Dilution | 1.14% | -1.47% | 0.98% | -3.09% | 0.58% | 1.06% | Upgrade
|
| Total Shareholder Return | 3.95% | 0.68% | 0.98% | -3.09% | 1.88% | 2.01% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.